Case series observes rapid plaque clearance with donanemab in Alzheimer’s disease, suggesting potential surrogate markers to optimize treatment duration.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: